Iatrogenic rheumatic syndromes in the elderly

Clinics in Geriatric Medicine

Volumn 21, Issue 3 SPEC. ISS., 2005, Pages 577-588

  Quiceno, G Andres ^a   Cush, John J ^a  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALCOHOL; ALLOPURINOL; AMINOSALICYLIC ACID; AMPHETAMINE; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTITHYROID AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CARBAMAZEPINE; CARBIDOPA; CARDIAC AGENT; CERIVASTATIN; CHLORPROMAZINE; COCAINE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC AGENT; DIURETIC AGENT; DOCETAXEL; ESTROGEN DERIVATIVE; ETANERCEPT; ETHAMBUTOL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; FLUORIDE; GOLD SALT; GRISEOFULVIN; HEPATITIS B VACCINE; HISTONE ANTIBODY; HORMONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERFERON; ISONIAZID; LEVODOPA; LITHIUM; MACROLIDE; METHYLDOPA; MEVINOLIN; MINOCYCLINE; MONTELUKAST; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLIN G; PENTAZOCINE; PHENYTOIN; PRAVASTATIN; PROCAINAMIDE; PROPYLTHIOURACIL; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINIDINE; RESERPINE; RETINOL; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SIMVASTATIN; TERBINAFINE; TETRACYCLINE; THIAMAZOLE; TICLOPIDINE; TRYPTOPHAN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

APLASTIC ANEMIA; ARTHRALGIA; DISSEMINATED INTRAVASCULAR CLOTTING; EOSINOPHILIA; EXFOLIATIVE DERMATITIS; FEVER; GERIATRICS; GOUT; GRAPEFRUIT JUICE; HEPATITIS; HUMAN; HYPERURICEMIA; IATROGENIC DISEASE; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS; MYALGIA; MYOPATHY; MYOSITIS; NEPHROLITHIASIS; RASH; REVIEW; RHABDOMYOLYSIS; RHEUMATIC DISEASE; SCLERODERMA; SHOCK; SIDE EFFECT; SKIN NECROSIS; SYSTEMIC VASCULITIS; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS;

EID: 19444363119     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2005.02.004     Document Type: Review

References (40)

1. P.D. Thompson, P. Clarkson, and R.H. Kara Statin associated myopathy JAMA 289 13 2003 1681 1690
2. S.M. Jamal, M.J. Eisenberg, and S. Chrsitopoulos Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors Am Heart J 147 6 2004 956 965
3. C.M. Ballantyne, A. Corsine, and M.H. Davidson Risk of myopathy with statin therapy in high-risk patients Arch Intern Med 163 2003 553 564
4. A.J. Daugird, and K. Crowell Do statins cause myopathy? J Fam Pract 52 12 2003 973 976
5. R.C. Pasternak, S.C. Smith, and C.N. Bairey-Merz ACC/AHA/NIHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2000 567 572
6. A.K. Mantel-Teeuwise Myopathy due to statin/fibrate use in the Netherlands Ann Pharmacother 36 12 2002 1957 1960
7. D. Gaist Lipid-lowering drugs and risk of myopathy: a population-based follow-up study Epidemiology 12 5 2001 565 569
8. J.C. Prieto Safety profile of statins Rev Med Chil 129 11 2001 1237 1240
9. M. Evans, and A. Rees Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all the statins the same? Drug Saf 25 9 2002 649 663
10. F.J. Borrego Rhabdomyolisis and acute renal failure secondary to statins Nefrologia 21 3 2001 309 313
11. J.C. Reineveld Differen effects of 3-hydroxy-3methylgluaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats Pediatr Res 39 6 1996 1028 1035
12. D. Williams, and J. Feeley Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin Pharmacokinet 41 5 2002 343 370
13. E.E. Slater Mechanism of action and biological profile of HMG CoA reductase inhibitors Drugs 36 Suppl 3 1998 72 82
14. A. Corsini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmachol Ther 84 1999 413 428
15. R. Paoiletti Pharmacological interactions of statins Atheroscler Suppl 3 1 2002 35 40
16. S. Matzno, K. Tazuya-Murayama, and H. Tanaka Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis J Pharm Pharmacol 55 6 2003 795 802
17. P.S. Phillips, R.H. Hass, and S. Bannykhs Statin-associated myopathy with normal creatinine kinase levels Ann Intern Med 137 7 2002 581 585
18. J.A. Farne Statin and myotoxicity Curr Atheroscler Rep 5 2 2003 96 100
19. A.A. Carvalho Statin and fibrate associated myopathy: study of eight patients Arq Neuropsiquiatr 62 2A 2004 257 261
20. E. Calkins, and A. Vladutiu Drug induced lupus. Musculoskeletal disorders E.H. Duthie P. Katz Practice of geriatrics 3rd ed 1998 WB Saunders Philadelphia 430
21. N.J. Olsen Drug-induced autoimmunity Baillieres Best Pract Res Clin Rheumatol 18 5 2004 677 688
22. D.L. Blazes, and G.J. Martin Drug-induced lupus erythematosus secondary to nafcillin: the first reported case Rheumatol Int 24 4 2004 242 243
23. J.P. Buyon Drug-related Lupus Primer on the rheumatic diseases 12th ed 2001 The Arthritis Foundation Atlanta (GA) 345
24. F.F. Ferri Systemic Lupus Erythematosus F.F. Ferri Practical guide to the care of the medical patient 6th ed 2004 Mosby, Inc. St. Louis 810 811
25. M.G. Cohen, and M.V. Prowse Drug-induced rheumatic syndromes. Diagnosis, clinical features and management Med Toxicol Adverse Drug Exp 4 3 1989 199 218
26. R.A. Asherson, and J. Zulman Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies Ann Rheum Dis 48 3 1989 232 235
27. P.W. Turgeon, and T.L. Slamovits Scleritis as the presenting manifestation of procainamide-induced lupus Ophthalmology 96 1 1989 68 71
28. E.F. Sherertz Lichen planus following procainamide-induced lupus erythematosus Cutis 42 1 1988 51 53
29. D. Maxwell, and R. Silver Laryngeal manifestations of drug induced lupus J Rheumatol 14 2 1987 375 377
30. S.S. Wing, and I.G. Fantus Adverse immunological effects of antithyroid drugs CMAJ 136 2 1987 12 17
31. J.J. Cush, and A.F. Kavanaugh Drug-induced lupus J.J. Cush A.F. Kavanaugh Rheumatology diagnosis and therapeutics 1999 Williams & Wilkins Baltimore (MD) 193 197
32. A. Epstein, and P. Barland The diagnostic value of antihistone antibodies in drug-induced lupus erythematosus Arthritis Rheum 28 2 1985 158 162
33. V.J. Bray, S.G. West, and K.T. Schultz Antihistone antibody profile in sufasalazine induced lupus J Rheumatol 21 11 1994 2157 2158
34. R.L. Rubin Etiology and mechanism of drug-induced lupus Curr Opin Rheumatol 11 5 1999 357 363
35. K.Y. Kim, H. Ralph Schumacher, and E. Hunsche A literature review of the epidemiology and treatment of acute gout Clin Ther 25 2003 1593 1617
36. K.T. Rott, and C.A. Agudelo Gout JAMA 289 2003 2857 2860
37. J.J. Cush, A. Kavanaugh, and M.F. Stein Gout J.J. Cush A. Kavanaugh M.F. Stein Rheumatology: diagnosis and therapeutics 2005 Lippincott Williams & Wilkins Philadelphia 187 195
38. K.H. Boomershine Colchicine-induced rhabdomyolysis Ann Pharmacother 36 5 2002 824 826
39. S.M. ten Holder, M.S. Joy, and R.J. Falk Cutaneous and systemic manifestations of drug-induced vasculitis Ann Pharmacother 36 1 2002 130 147
40. M.K. Doyle, and M.L. Cuellar Drug-induced vasculitis Expert Opin Drug Saf 2 4 2003 401 409